QTQinglin Tan

Qinglin Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qinglin Tan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Chen

    Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people’s hospital), Dongguan, China

    1 shared publication
  • Guobiao Chen

    Department of Thoracic Surgery, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan, China

    1 shared publication
  • Hanbin Zhang

    Department of Clinical Pharmacy, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s hospital), Dongguan, China

    1 shared publication
  • Huiting Mo

    Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan people’s hospital), Dongguan, China

    1 shared publication
  • Jianming Lu

    Department of Andrology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China

    1 shared publication
  • Jiaqi Liao

    Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Unveiling HJURP as a Biomarker of Poor Prognosis and Immunotherapy Resistance in Lung Adenocarcinoma: A Multicenter Study

    by Qinglin Tan, Peiliang Kong, Guobiao Chen, Chen Chen, Huiting Mo, Yuancheng Huang, Manman Zhang, Yanmin Cai, Hanbin Zhang, Jianming Lu, et al.

    Background: Lung adenocarcinoma (LUAD) is the most common lung cancer, associated with high metastasis and low survival rates. Identifying reliable biomarkers is essential for better prognosis and treatment. Methods: In this study, we analyzed RNA sequencing data, mutation information, and clinical data from the TCGA-LUAD cohort and other multicenter datasets to investigate the role of Holliday junction recognition protein (HJURP) in LUAD. We employed immunohistochemistry in tissue microarray cohort to validate the prognostic significance of HJURP. The DepMap project was used to validate the effect of HJURP knockout in vitro. Results: Holliday junction recognition protein was identified as an adverse prognostic factor in the TCGA-LUAD cohort and diverse ethnic groups. Its expression correlated with poor immunotherapy outcomes, and HJURP knockout suppressed cancer cell proliferation. High HJURP expression was linked to increased mutation frequency, particularly in TP53 and TTN. Pan-cancer analysis also indicated HJURP as a poor prognostic factor in various solid tumors. Conclusions: Holliday junction recognition protein emerges as a significant biomarker in LUAD, consistently associated with poor prognosis across multiple cohorts. Its role in various oncogenic pathways and correlation with advanced disease stages underscore the potential of HJURP as a target for therapeutic intervention and as a marker for prognosis in LUAD.

  • Open Access

    miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer

    by Jing Guo, Xuxian Zhong, Qinglin Tan, Shengnan Yang, Jiaqi Liao, Jinke Zhuge, Ziyang Hong, Qiong Deng, Qiang Zuo

    Trastuzumab resistance negatively influences the clinical efficacy of the therapy for human epidermal growth factor receptor 2 (HER2) positive gastric cancer (GC), and the underlying mechanisms remain elusive. Exploring the mechanisms and finding effective approaches to address trastuzumab resistance are of great necessity. Here, we confirmed that endoplasmic reticulum (ER) stress-induced trastuzumab resistance by up-regulating miR-301a-3p in HER2-positive GC cells. Moreover, we elucidated that miR-301a-3p mediated trastuzumab resistance by down-regulating the expression of leucine-rich repeats and immunoglobulin-like domains containing protein 1 (LRIG1) and subsequently activating the expression of insulin-like growth factor 1 receptor (IGF-1R) and fibroblast growth factor receptor 1 (FGFR1) under ER stress. We also found that intercellular transfer of miR-301a-3p by exosomes disseminated trastuzumab resistance. The present study demonstrated that exosomal miR-301a-3p could serve as a non-invasive biomarker for trastuzumab resistance, which was maybe a novel potential therapeutic target to overcome trastuzumab resistance and improve the curative effect of trastuzumab in HER2-positive GC patients.